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Abstract
Pollution, including polycyclic aromatic hydrocarbons (PAH), may contribute to increased
prevalence of asthma. PAH can bind to the Aryl hydrocarbon Receptor (AhR), a transcrip-
tion factor involved in Th17/Th22 type polarization. These cells produce IL17A and IL-22,
which allow neutrophil recruitment, airway smooth muscle proliferation and tissue repair
and remodeling. Increased IL-17 and IL-22 productions have been associated with asthma.
We hypothesized that PAH might affect, through their effects on AhR, IL-17 and IL-22 pro-
duction in allergic asthmatics. Activated peripheral blood mononuclear cells (PBMCs) from
16 nonallergic nonasthmatic (NA) and 16 intermittent allergic asthmatic (AA) subjects were
incubated with PAH, and IL-17 and IL-22 productions were assessed. At baseline, activated
PBMCs from AA exhibited an increased IL-17/IL-22 profile compared with NA subjects. Die-
sel exhaust particle (DEP)-PAH and Benzo[a]Pyrene (B[a]P) stimulation further increased
IL-22 but decreased IL-17A production in both groups. The PAH-induced IL-22 levels in
asthmatic patients were significantly higher than in healthy subjects. Among PBMCs, PAH-
induced IL-22 expression originated principally from single IL-22- but not from IL-17- ex-
pressing CD4 T cells. The Th17 transcription factors RORA and RORC were down regulat-
ed, whereas AhR target gene CYP1A1 was upregulated. IL-22 induction by DEP-PAH was
mainly dependent upon AhR whereas IL-22 induction by B[a]P was dependent upon activa-
tion of PI3K and JNK. Altogether, these data suggest that DEP-PAH and B[a]P may
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contribute to increased IL22 production in both healthy and asthmatic subjects through
mechanisms involving both AhR -dependent and -independent pathways.
Introduction
Allergic asthma has strongly increased in the last decades in western countries and is consid-
ered mainly as a Th2 mediated disease. There is increasing evidence that environmental pollu-
tion contributes to this augmented prevalence [1]. In particular, we and others have shown that
Polycyclic Aromatic Hydrocarbons derived from diesel exhaust particles (DEP-PAH) play an
inflammatory and adjuvant role in the development and exacerbation of allergic inflammation
by skewing the immune response towards a Th2 profile [2–5].
It is now clear that the biological response to many environmental pollutants is a direct con-
sequence of their interactions with the Aryl hydrocarbon Receptor (AhR), a cytosolic transcrip-
tion factor which binds exogenous ligands such as PAH or 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), as well as endogenous ligands derived from tryptophane metabolism such as 6-for-
mylindolo[3,2-b] carbazole (FICZ). Recent data suggest that AhR may be a major transcription
factor involved in the development of the Th17 and Th22 subsets [6–8]. The human Th17 sub-
population is characterized by the production of IL-17A, IL-17F, IL-22 and CCL20 [9], and the
expression of RORα and RORC [10], whereas the Th22 subpopulation produces IL-22 but not
IL-17A [7]. IL-17A and IL-22 are both involved in neutrophilic influx, airway smooth muscle
cell proliferation and migration [11–14], and IL-22 is also involved in tissue repair and remod-
eling mechanisms [15]. In agreement with the presence of these endpoints in asthma, increased
levels of IL-17A, IL-17F and IL-22 are found at the circulating and lung levels in allergic asth-
matic patients as compared with controls [16–18].
Although AhR has been consistently involved in IL-22 production by T cells [7,19], contro-
versial results have been obtained for IL-17A production. Indeed, some AhR ligands such as
TCDD and FICZ have been shown to induce IL-17A production in mice [6–8] and to inhibit it
in humans [7,19,20]. Moreover, AhR has been shown to favour IL-10-producing regulatory T
cells according to other studies in both mice and humans [21,22]. These apparently contradic-
tory results may relate to the ligand used (endogenous favouring IL17 versus exogenous favour-
ing IL-10) [6,8], to the species [7,8], to the culture conditions (i.e. added cytokines) [19,23,24]
but also to the cells expressing AhR. Indeed, besides CD4 T cells, CD8 T cells and dendritic
cells also express AhR. Despite these discrepancies, these studies suggest a potential link be-
tween environmental pollutants able to bind to AhR, and the Th17/Th22 program. Therefore,
we hypothesized that DEP-PAH, and some purified PAH previously shown to be involved in
asthma, might affect, through their effects on AhR, IL-17 and IL-22 cytokine profiles.
In the present study, activated peripheral blood mononuclear cells from allergic asthmatics
exhibited an increased Th17/Th22 type profile compared with nonallergic nonasthmatic sub-
jects. Only some of the PAH tested including DEP-PAH- and Benzo[a]pyrene- (B[a]P) exacer-
bated IL-22 production by stimulated mononuclear cells, whereas IL-17 production was
inversely down regulated in asthmatic as well as healthy subjects. The mechanisms of regula-
tion of IL-22 induction were dependent upon AhR, and also involved Mitogen-activated pro-
tein kinase (MAPK) and Phosphotidylinositol 3-kinase (PI3K) pathways.
PAH and Th17 Type Cytokines in Asthma
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Materials and Methods
Human donors
Venous blood was collected from 16 healthy nonallergic nonasthmatic (NA) subjects, with neg-
ative skin prick tests and no specific IgE to common environmental allergens, and from 16 al-
lergic asthmatic (AA) patients. All these patients had a clinician’s diagnosis of asthma, and
exhibited positive skin prick tests and specific IgE (more than 3 KU/L) towards at least one al-
lergen. Skin prick testing included house dust mite, grass and tree pollens, cat and dog danders
as well as fungi. Exclusion criteria included upper or lower respiratory tract infection within
one month of study, use of anti-inflammatory controller medications within four weeks of
study, significant non-asthma pulmonary disease or other medical problems. All subjects were
non-smokers. To exclude the potential confounding effects of steroid treatment, only intermit-
tent asthmatic subjects taking only β2 agonists as needed, according to GINA guidelines, were
included. Among potential confounding factors for IL-17 and IL-22 expression, we anticipated
severity of the disease, recent infections and smoking, however we cannot exclude uncontrolled
factors such as encountered environmental pollution or diet. The subject’s characteristics are
shown in S1 Table. The study was approved by the Centre Hospitalier Régional Universitaire
of Lille Ethical Review Committee (Number 2008/010) and all donors signed an informed
consent form.
Cell purification and culture
As there are some controversies about the effect of AhR ligands on the production of IL-17
which may relate to the use of particular single cell types (memory, naïve CD4 T cells, T cells
during cytokine induced differentiation, etc.), we evaluated the effects of PAH in an environ-
ment where all these cell types are represented and can interact, in particular with dendritic
cells, i.e. peripheral blood mononuclear cells (PBMCs). These cells were prepared from blood
collected on heparin as previously described [25]. To activate Th17/Th22 cells, we used a surro-
gate of antigen stimulation, through CD3 combined with co-stimulation by CD28. Preliminary
experiments were performed to determine the minimal dose of CD3 antibody allowing IL-17
production. Concentrations between 10μg/mL and 1ng/mL were tested which showed that the
100ng/mL concentration reproducibly induced production of IL-17 by PBMCs. Moreover pre-
liminary kinetics experiments performed between 24 and 96hr after stimulation showed that
the highest level of IL-17 was observed 72 hrs after stimulation, this time point was therefore
chosen for the study. PBMCs (2.106/ml) were stimulated in 48-well flat-bottomed microculture
plates coated with the minimal anti-CD3 concentration (100ng/ml, OKT3 clone) and soluble
anti-CD28 (2μg/ml; BD Biosciences) in complete Iscove's modified Dulbecco's medium (Invi-
trogen Corporation, Carlsbad, CA, USA), a medium previously shown to favour IL-17 produc-
tion [26]. A mix of DEP-PAH standard reference material (SRM 1975, Interchim, Montluçon,
France) as well as different purified PAH including the prototypical PAH Benzo[a]Pyrene (B
[a]P), and two PAH previously shown to increase allergen-induced asthmatic responses
[27,28], 9–10 Phenanthrene quinone (PHEQ), and anthracene (ANT) (Sigma-Aldrich, St
Louis, MO, USA), were dissolved in 0.02% dimethyl sulfoxide (DMSO) and used at optimal
non-cytotoxic doses (150ng/ml for SRM, 250ng/ml for B[a]P, 75nM for PHEQ and 1μM for
ANT). In all experiments the cell viability was more than 95%, as assessed by trypan blue exclu-
sion. DMSO was used as control. The supernatants and cells were collected after 72hr of cul-
ture. In some experiments, inhibitors as well as Th17 conditions were used. AhR antagonist
CH-223191 (3μM; Calbiochem, Darmstadt, Germany), inhibitors of p38 kinase (SB203580,
1μM; Merck KGaA, Darmstadt, Germany), c-jun N-terminal kinase (JNK) (SP600125, 20 μM;
PAH and Th17 Type Cytokines in Asthma
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Merck KGaA), MAP kinase kinase (MEK/ERK) (PD98059, 25 μM; Merck KGaA) or Phospha-
tidylinositol 3-kinase (PI3K) (LY294002, 10 μM: Merck KGaA) all used at non-cytotoxic con-
centrations were added to the cultures at the same time as the different stimuli. We used the
AhR antagonist CH-223191 to inhibit AhR since it has been shown to exhibit a very high an-
tagonist activity, while being not toxic [29]. For Th17 conditions stimulated PBMCs were cul-
tured with IL-2, IL-6 (PeproTech, London, United Kingdom), IL-1β (eBiosciences, San Diego,
CA, USA) and IL-23 (Miltenyi Biotec, Paris, France) all at 10ng/mL for 6 days.
Cytokine secretion assays
Cytokines were measured by ELISA according to the manufacturer’s recommendations. IL-
17A, IL-22, CCL20, IL-13, IL-5, IL-10, TGF-β1, periostin and CCL18 kits were from R&D sys-
tems (Minneapolis, MN, USA), IL-17F from eBiosciences and IFN-γ from BD Biosciences
(Franklin Lakes, NJ, USA). The lower detection limit was 15.6 pg/ml for IL-17A, IL-17F and
CCL20, 31.2 pg/ml for IL-22, IL-5, IFN-γ, and TGF-β, 93.8 pg/ml for IL-13, 375 pg/ml for peri-
ostin and 7.8 pg/ml for CCL18.
Quantitative Real Time PCR
Quantitative real Time PCR was performed as previously described [30]. Briefly Total RNA
was isolated using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions.
Reverse transcription was performed using random primers and M-MLV enzyme (Invitrogen).
Real-time PCR quantification was performed using a SYBR Green approach (Light Cycler;
Roche, Penzberg, Germany), and normalized to rs9 house keeping gene. The sequences of the
oligonucleotides are shown in S2 Table.
Flow Cytometry
IL-17 and IL-22 cell origin was determined by flow cytometry. Stimulated PBMCs (2.106/ml)
were incubated with HAP or DMSO with or without Th17 cytokines. At day 3 IL-2 was added
again. At day 6, cells were stimulated by PMA (50ng/ml; Sigma-Aldrich) and Ionomycin
(1μg/ml; Calbiochem) in the presence of Brefeldin A (10μg/ml; Sigma-Aldrich) for 4h. Cell
surface and intra cellular staining was performed as previously described [31]. Specific cell
populations were identified using the following combination of antibodies CD4-FITC+ (clone
RPA-T4), CD8-PE+ (clone HIT8a) for T cells; CD3-FITC- (clone HIT3a) CD56-PE+ (clone
B159) for NK cells; iNKT-PE+ (clone 6B11) for iNKT cells; Lin2-FITC- (clones NCAM 16.2,
MFP9, SK7, SJ25C1, L27) CD123-PE+/- (clone 7G3) HLA-DR-V450+ (clone G46.6) for den-
dritic cells (DCs) (BD Biosciences) and intracellular staining using IL-17A-APC (clone eBio64-
DEC17), IL-22-PERCP eFluor710 (clone 22URTI) (eBiosciences). Mouse IgG1-APC,
IgG1-PERCP eFluor710 isotypes (clone P3.6.2.8.1) were from eBiosciences. Living cells were
gated using forward and side scatter properties, and further using livedead fixable aqua dead
cell stain kit (Life technologies, St Aubin, France) and then cell populations were gated using
the specific markers indicated above. Data were acquired on a BD LSR Fortessa flow cytometer
using the DIVA software (version 6.1.3). Compensations were calculated using BD Compbeads
with the automatic compensation programme. Data were expressed as percentage of cytokine
positive cells among the considered population after subtraction of the control isotype.
Statistical Analyses
Data were normally distributed (Shapiro wilk test) except for CCL18. For CCL18, data were
analysed using non-parametric Friedman analysis of variance followed by Dunn’s post hoc
PAH and Th17 Type Cytokines in Asthma
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test. For the other parameters, within NA/AA comparisons were performed using one way
ANOVA followed by Holm-Sidak’s multiple comparison test, and between NA/AA compari-
sons using unpaired t-test. Statistical analyses were performed using GraphPad Prism 6 soft-
ware (La Jolla, CA, USA). Values of p<0.05 were regarded as statistically significant. As this
was an exploratory study, no adjustment for multiple testing was performed.
Results
Stimulated PBMCs from AA patients exhibit an exacerbated Th17 type
cytokine and mRNA profile compared with NA subjects
Previous studies have evidenced that allergic asthmatics exhibit higher levels of IL-17/IL-22 in
the lung and sera than healthy subjects [16,17]. To evaluate if this difference was also found in
PBMCs, Th17 type cytokine production was measured in anti-CD3/CD28 stimulated PBMCs.
Indeed, almost no production of cytokines was found in the supernatants without anti CD3/
CD28 stimulation, whatever the allergic status. IL-17A, IL-17F, and IL-22 but not CCL20, were
increased in stimulated PBMCs from AA patients compared with NA subjects (Fig 1A). Levels
of Th2- (IL-13, IL-5, periostin), Th1- (IFN-γ) and Tregulatory- (TGF-β1 and IL-10) type cyto-
kines were not significantly different between NA and AA donors after anti CD3/CD28 stimu-
lation (data not shown). Furthermore, the lineage-specifying Th17/Th22 transcription factors
RORC, AhR target gene CYP1A1, but not RORA were upregulated in AA compared with NA
subjects (Fig 1B).
DEP-PAH and B[a]P drive reciprocal regulation of IL-17A and IL-22
production by PBMCs
To assess the ability of different PAH to modulate the production of Th17/Th22 type cytokines,
activated PBMCs were co-incubated with SRM or with purified PAH. It is of note that PAH
were not able to induce IL-17 or IL-22 production by unstimulated PBMCs. B[a]P decreased
Fig 1. Th17/Th22 type profile of anti-CD3/CD28-activated peripheral bloodmononuclear cells. A
Cytokine secretion by activated peripheral blood mononuclear cells from nonallergic (NA) subjects (n = 10)
and allergic asthmatic (AA) patients (n = 12), was evaluated at 72hr by ELISA and expressed as mean ± SEM
ng/ml.BGene mRNA level in activated peripheral blood mononuclear cells from NA subjects (n = 8) and AA
patients (n = 11), was evaluated at 72hr by Q-RT-PCR and expressed as mean relative expression (RE) of 2^
(-ΔCt) ± SEM, where the ΔCt value of the sample was determined by subtracting the Ct value of the target
gene from the Ct value of the rs9 house keeping gene. *P<.05, **P<.01, and ***P<.001.
doi:10.1371/journal.pone.0122372.g001
PAH and Th17 Type Cytokines in Asthma
PLOSONE | DOI:10.1371/journal.pone.0122372 April 10, 2015 5 / 15
IL-17A secretion by stimulated PBMCs in both groups, whereas SRM decreased it only in AA
patients (Fig 2). No effects were observed for ANT and PHEQ (Fig 2). IL-17F was slightly de-
creased in the presence of B[a]P, and only in AA patients (S1 Fig), and CCL20 was not modi-
fied (data not shown). An opposite effect was observed on IL-22 for SRM and B[a]P with
increased secretion of IL-22 with a similar magnitude in healthy and asthmatic subjects, but
with a final level significantly higher in AA patients than in NA subjects (Fig 2). PHEQ and
ANT did not modify IL-22 production. As previously described [2–4], IL-13 production was
significantly increased in DEP-PAH- and B[a]P- stimulated PBMCs from asthmatic (respec-
tively 1.77 ± 0.27 and 1.73 ± 0.25 versus 1.28 ± 0.27 ng/ml for controls, p<0.05) but not from
healthy subjects. Inhibition of IL-17A by PAH was not related to the induction of the regulato-
ry cytokines IL-10 (Fig 2) or TGF-β1 (S1 Fig). In contrast, CCL18, a chemokine with immuno-
regulatory properties [25,31,32] was inhibited in response to B[a]P in both groups and by
DEP-PAH in asthmatics (S1 Fig). PHEQ and ANT did not modify the production of IL-10 and
CCL18 and therefore were not furthermore evaluated. To evaluate if the reciprocal regulation
of IL17 and IL22 induced by PAH changed with the culture conditions, PBMCs were cultured
in Th17 conditions. A similar pattern of IL-22 induction and IL-17 reduction by B[a]P was still
observed, although with a higher level of cytokine production, and with significant differences
between NA and AA subjects for IL-22 (Fig 3A). Collectively, these results suggest that some
PAH promote the secretion of IL-22 and concomitantly inhibit IL-17A production in PBMCs
from both healthy and asthmatic donors, independently of the culture cytokine conditions.
DEP-PAH and B[a]P increase the percentage of IL-17- IL-22+ CD4+ T
cells
Among PBMCs, CD4, CD8, NK, NKT and DCs have been shown to produce IL-22. To evalu-
ate which sub populations were able to express IL-22 in response to PAH stimulation, IL-22
Fig 2. Cytokine profile of PAH-stimulated peripheral bloodmononuclear cells in allergic asthmatics
(AA) and nonallergic subjects (NA). IL-17A, IL-22 and IL-10 secretion by activated peripheral blood
mononuclear cells from NA subjects (n = 10) and AA patients (n = 12) stimulated or not with different PAH for
72hr was determined by ELISA. Results are expressed as mean ± SEM. *P<.05 and **P<.01 versus control.
#P<.05 and ##P<.01 AA versus NA subjects.
doi:10.1371/journal.pone.0122372.g002
PAH and Th17 Type Cytokines in Asthma
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cell origin was determined by flow cytometry following DEP-PAH and B[a]P stimulation. Al-
though cytokine production was different in quantity between AA and NA, there was no signif-
icant difference in the percentage of cytokine positive cells between the two groups, therefore
the data were mixed. As compared with control stimulated PBMCs, DEP-PAH and B[a]P acti-
vation in Th17 conditions induced a significant increase in IL-22-expressing CD4+ T cells but
not in IL-22-expressing CD8+ cells or DCs (Fig 3B). B[a]P activation also significantly de-
creased the percentage of IL-17-expressing CD4+ cells (Fig 3B). IL-22 expression induced by
PAH activation in CD4 cells was observed mainly in IL-17 negative CD4+ cells (Fig 3B). A rep-
resentative flow cytometry profile is shown in S2 Fig Similar distribution was obtained in non
Th17 conditions (data not shown). No expression of IL-22 and IL-17 was observed in NK cells
and monocytes, and NKT cells did not survive in our culture conditions. Thus, among total
PBMCs, DEP-PAH- and B[a]P- induced IL-22- positive cells were mainly non Th17 CD4+
T cells.
B[a]P and DEP-PAH inhibit RORC, RORA and NOTCH whereas they
increase AhR target gene CYP1A1 expression
To understand the mechanisms underlying the modified cytokine profile in response to PAH,
a number of Th17/Th22-related transcriptions factors were evaluated. Besides the key lineage
transcription factors RORα and RORc for Th17 cells and AhR for Th17/Th22 cells, BATF and
Notch have been associated to Th17 [33,34] and BNC2 and Notch to Th22 differentiation
Fig 3. Cytokine profile and cell expression of PAH-stimulated peripheral bloodmononuclear cells
cultured in Th17 conditions. A IL-17A and IL-22 production by activated peripheral blood mononuclear
cells from 6 nonallergic (NA) subjects and 6 allergic asthmatic (AA) patients stimulated or not with SRM or B
[a]P for 6 days was determined by ELISA. Results are expressed as mean ± SEM. *P<.05 versus
corresponding control. #P<.05 AA versus NA subjects.B Activated peripheral blood mononuclear cells were
stimulated or not with SRM and B[a]P, stained with antibodies against cytokine and cell surface markers, and
evaluated by flow cytometry. Results are expressed as mean ± SEM percentage of cytokine positive cell
populations for n = 7–11 subjects. *P<.05 versus corresponding control, ##P<.01, ###P<.001.
doi:10.1371/journal.pone.0122372.g003
PAH and Th17 Type Cytokines in Asthma
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[15,35]. In agreement with the cytokine protein data, SRM stimulation inhibited RORA and
RORC only in AA patients, and induced AhR target gene CYP1A1 expression in both groups
(Fig 4). The differential effect observed for B[a]P on IL-17 and IL-22 production was reflected
at the transcriptional level, with inhibition of RORA and RORC in both groups and of NOTCH
only in AA patients, and increases in AhR target gene CYP1A1 in both groups (Fig 4). In con-
trast, BATF and BNC2 were not modified. Collectively, these results show that PAH-induced
down regulation of IL-17A paralleled transcriptional inhibition of RORA and RORC, as well as
NOTCH in AA patients, whereas upregulation of IL-22 resembled activation of AhR.
IL-22 induction by DEP-PAH is dependent upon AhR
To determine the contribution of AhR to IL-17 and IL-22 regulation by PAH, we used the spe-
cific AhR antagonist CH-223191 [29]. Activated control cells treated with CH-223191 exhib-
ited decreased production of IL-22 (Fig 5), consistent with previous observations that
endogenous AhR ligands are induced by anti-CD3/CD28 stimulation and present in culture
medium [19,26]. In both groups, IL-22 induced production in SRM-stimulated conditions was
almost completely inhibited by the AhR antagonist, reaching the same level as antagonist-treat-
ed control cells (dotted line) (Fig 5) showing that both endogenous and exogenous AhR-in-
duced IL-22 production was AhR dependent. In B[a]P-stimulated conditions, the enhancing
effect on IL-22 secretion was only half reversed by the AhR antagonist at levels corresponding
to the inhibition of the endogenous AhR-induced IL-22 alone. In activated control cells, AhR
antagonist induced increased level of IL-17A in both groups (Fig 5), but no significant modifi-
cations of IL-17F, CCL18 (S3 Fig) and CCL20 secretion (data not shown). As SRM stimulation
induced IL-17 modifications only in AA patients (Fig 2), the antagonist was tested in this con-
dition only in these patients. Upon SRM stimulation, IL-17A production in AA was significant-
ly restored by the antagonist but not to the level of the antagonist-treated control cells (dotted
line) (Fig 5). In B[a]P-stimulated conditions, the inhibitory effect on IL-17A production was
not reversed by the AhR antagonist in both groups (Fig 5). The effect of B[a]P on CCL18
Fig 4. Transcript levels of genes involved in Th17/Th22 polarization. Activated PBMCs from nonallergic (NA) subjects (n = 8) and allergic asthmatic (AA)
patients (n = 11) were incubated with or without PAH for 72hr, and gene mRNA level was assessed by Q-RT-PCR. Results are expressed as mean relative
expression (RE) of 2^(-ΔCt) ± SEM, where the ΔCt value of the sample was determined by subtracting the Ct value of the target gene from the Ct value of the
rs9 house keeping gene. *P<.05,**P<.01, #P<.05 and ##P <.01 AA versus NA subjects.
doi:10.1371/journal.pone.0122372.g004
PAH and Th17 Type Cytokines in Asthma
PLOSONE | DOI:10.1371/journal.pone.0122372 April 10, 2015 8 / 15
production in both groups and on IL-17F in AA patients was not dependent on AhR (S3 Fig).
Altogether, these results suggest that AhR is a major pathway in DEP-PAH- induced IL-22
production, whereas other pathways might contribute to B[a]P-induced IL-22/IL-17A
imbalance.
PI3K, JNK and ERK participate in the enhancing effect of B[a]P on IL-22
production
B[a]P has been shown to have effects independent of the AhR pathway through the activation
of MAPK [36], therefore the involvement of different kinases was investigated in B[a]P-stimu-
lated PBMCs. PI3K and JNK inhibitors totally inhibited IL-22 induction in B[a]P-stimulated
cells in NA subjects, and less importantly in AA patients (Fig 6). ERK inhibitor also displayed a
potent inhibitory effect on B[a]P induced IL-22, again more important in NA than in AA sub-
jects. In contrast, p38 inhibitor did not significantly modify IL-22 production in either group
(Fig 6). For IL-17A production, the inhibitory effect induced by B[a]P was not restored to the
level of control cells but was reduced with PI3K, JNK p38 and ERK inhibitors showing that
these kinases are in fact inducers of IL-17A, and are not involved in IL-17A inhibition by BaP
(Fig 6). Overall, these data suggest that PI3K JUNK and ERK are involved in IL-22 induction
by B[a]P, whereas IL-22 induction by DEP-PAH is mainly mediated by AhR.
Discussion
The aim of this study was to evaluate the involvement of PAH in IL-22 and IL-17 production
in asthmatic patients, as recent studies point out a participation of these cytokines in some end-
points of asthma. Without PAH stimulation, anti-CD3/CD28-activated T cells from AA
Fig 5. Effects of AhR antagonist on IL-22 and IL-17A secretion by peripheral bloodmononuclear cells
from Allergic asthmatics (AA) and nonallergic subjects (NA). Activated peripheral blood mononuclear
cells from NA subjects (n = 10) and AA patients (n = 12) were incubated or not with PAH, in the presence or
not of AhR antagonist CH-223191 for 72hr, and cytokine production was assessed by ELISA in the
supernatants. Results are expressed as mean ± SEM. *P<.05, **P<.01. The dotted line is set on the level of
the antagonist-treated control cells.
doi:10.1371/journal.pone.0122372.g005
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patients exhibited higher expression of the master Th17 transcription factors RORC and of the
AhR target gene CYP1A1 than NA subjects, which were associated with increased levels of IL-
17A, IL-17F and IL-22 cytokines, suggesting that AA patients might display a higher sensitivity
to the induction of the Th17/Th22 profile than NA subjects after polyclonal activation. Howev-
er, there was no difference in the Th2 profile between AA and NA donors after polyclonal stim-
ulation. These data are in agreement with the literature showing that in contrast to antigen-
mediated activation, polyclonally stimulated PBMCs exhibit similar IL-13 and IL-4 production
in allergic and control subjects [37,38].
DEP-PAH and B[a]P stimulation exacerbated IL-22 secretion but inhibited the production
of IL-17A. These data are in contrast to mouse studies where the AhR ligands TCDD and FICZ
induce both cytokines [6–8], indicating possible species-specific effects of AhR agonists.
Fig 6. Effects of kinase inhibitors on IL-22 and IL-17A secretion. Activated peripheral blood mononuclear
cells from nonallergic (NA) subjects (n = 8) and allergic asthmatic (AA) patients (n = 8) were incubated or not
with PAH and with or without inhibitors of kinases for 72hr, and cytokine production was evaluated by ELISA
in the supernatants. Results are expressed as mean ± SEM. *P<.05, **P<.01 ***P<.001. The dotted line is
set on the level of inhibitor-treated control cells for IL-22 and of control cells for IL-17 and indicates the level to
achieve for complete dependence upon the pathway evaluated.
doi:10.1371/journal.pone.0122372.g006
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Accordingly, differences in affinities of the mouse and human AhR have been observed for
their ligands [39]. In human studies, mainly differential regulation of IL-17A and IL-22 has
been previously observed [7,19,20]. In all these human studies, Th17 type cytokines were used
in the culture conditions, however In the present study, the same differential effect on IL-17
and IL-22 was observed whatever the presence or absence of Th17 differentiating cytokines.
This differential regulation was observed in both asthmatic and healthy subjects suggesting
that they were not related to the subject status. Another difference between all these studies, in-
cluding ours, is the use of different AhR agonists, which may explain the different outcomes, as
the mechanisms mediating the effects of AhR ligands still remain elusive and controversial
[40]. It is of note that although the chosen PAH have been shown to enhance allergen-induced
experimental asthma [27,28,41], only DEP-PAH and BaP modulated IL-17A and IL-22 pro-
duction, showing that not all AhR ligands behave similarly. Studies on human Th17 differenti-
ation have revealed that absence of TGF-β1 inhibits IL-17 while promoting IL-22 production
[24]. However, in our conditions, PAH stimulation did not modify TGF-β1 secretion, ruling
out such a mechanism. Similarly, although some AhR ligands such as TCDD have been shown
to favour IL-10 producing regulatory T cells in humans [22], PAH stimulation did not modify
IL10 production and did not induce CCL18, a chemokine with IL-10 dependent regulatory ef-
fect [25,31,32]. IL-22 originated mainly from CD4 T cells, which did not express IL-17, suggest-
ing that Th17 cells were not the origin of PAH-induced IL-22 intra cellular expression. It is of
interest that multiparameter hierarchical cluster analysis has highlighted the fact that in hu-
mans T cells, IL-22 producing T cells should be considered independently from the Th17 and
Th1 subsets [42]. These IL-22 producing T cells may be Th22 cells, as only few of them express-
ed intra cellular IL-4 (around 2%) or IFN-γ (around 5%). Although AhR is strongly expressed
by DCs [43], these cells did not contribute to PAH-induced IL-22 production in PBMCs. We
then evaluated the transcriptional events occurring after PAH activation. In mice, the tran-
scription factors RORγt and RORα, which control the generation of Th17 cells, seem to be the
most critical for IL-22 production [10], whereas in human T cells, AhR seems to be the major
transcription factor involved in IL-22 production [7]. In our conditions, PAH stimulation led
to decreased transcription of RORA and RORC genes, in agreement with the inhibitory effect
observed on IL-17A, and to increased AhR target gene CYP1A1 expression concomitantly to
IL-22 enhancement suggesting that PAH differentially regulate these cytokines at the transcrip-
tional level in humans. Among the other genes evaluated, NOTCH expression appeared associ-
ated with the inhibition of IL-17A, but only in AA patients, suggesting an involvement of this
pathway specifically in these patients. In favour of this hypothesis, polymorphisms of NOTCH
have been associated with asthma [44]. The role of AhR was evaluated using a specific antago-
nist. It inhibited IL-22 production, but it also increased endogenous AhR ligand-induced IL-
17A production, again suggesting an antagonistic regulation of these two cytokines by AhR,
at least in PBMCs and in response to endogenous ligands. Concerning exogenous ligands,
DEP-PAH-induced IL-22 production was totally dependent upon AhR, as the antagonist com-
pound abolished the entirety of the endogenous and exogenous AhR- induced IL-22 produc-
tion, whereas B[a]P-induced IL-22 secretion involved mainly kinases. It is of note that the
kinase inhibitors did not differentially regulate IL-22 and IL-17 and were not involved in IL17
inhibition. Thus, it is not clear what mechanisms drive the full inhibition of IL17 production
by PAH, and this will need further investigation.
Animal models of asthma have shown that IL-17A and IL-22 can be deleterious or protec-
tive. IL-17A can mediate steroid resistant inflammation and airway hyperresponsiveness [45]
whereas it can also negatively regulate established asthma [46]. IL-22 has been shown to con-
tribute to allergic asthma during the sensitization phase [17] and to promote lung immunopa-
thology during fungal allergy [47], but it can also inhibit antigen-induced eosinophil airway
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inflammation through inhibition of IL-25 [48], of IL-10 [49], or during the challenge phase
[17]. Interestingly, this ambivalence may relate to dose dependent effects, as IL-17A at low and
high doses exhibit opposite effects on Th2 airway inflammation with respectively an increase
and a decrease in eosinophil infiltration [50]. Similarly, in a model of epithelial tumorigenesis,
IL-22 induction at baseline is protective, whereas sustained high levels of IL-22 cause pro-
longed epithelial proliferation promoting intestinal tumours [51]. In our study, induction of
IL-22 by PAH was similarly observed in healthy and asthmatic donors but the final level was
higher in asthmatic subjects. In humans, increase in IL-22 has been associated with more severe
asthma [18], and IL-22 enhances human airway smooth muscle cell hyperplasia [11,12], epi-
thelial-mesenchymal transition in asthmatic bronchial epithelial cells [52], as well as cutaneous
remodeling [15]. Taken together, these studies suggest that limited or enhanced production of
IL-22 might respectively limit cell infiltration and promote tissue repair, including potentially
airway remodeling, although this requires further evaluation. Altogether, these data suggest
that some PAHmight contribute to increased IL-22 production in both healthy and asthmatic
patients, through mechanisms involving both AhR- dependent and independent pathways.
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